The latest complete version of cobimetinib instructions

Cobimetinib, trade name: Cotellic, is an oral kinase inhibitor mainly used to treat malignant tumors with specific gene mutations. Its primary indication is in combination with Vemurafenib (Vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma harboring BRAF V600E or V600K mutations. In addition, cobimetinib can also be used as a single agent to treat adult patients with histiocytic tumors. Before using cobimetinib, genetic testing must be performed to confirm whether the patient's tumor has the BRAF V600E or V600K mutation to ensure the suitability of the drug.

The mechanism of action of cobimetinib is to selectively inhibit the activity of MEK (mitogen-activated protein kinase kinase), thereby blocking the abnormal activation of the MAPK signaling pathway. This pathway is overactive in many cancers, promoting tumor cell proliferation and survival. By inhibiting MEK, cobimetinib can slow or prevent tumor growth and improve treatment efficacy. However, because this pathway is also involved in the regulation of normal cells, inhibiting MEK may lead to a series of side effects that require close monitoring during treatment.

In terms of usage and dosage, the standard recommended dose of cobimetinib is 60mg once a day, with 28 days as a treatment cycle, that is, continuous administration for 21 days and discontinuation of the drug for 7 days. This drug can be taken with food or alone, but skipping a dose should be avoided. If a patient misses a dose or vomits after taking the dose, the patient should not take a missed dose but should continue with the next dose as originally planned. If serious adverse reactions occur, doctors may adjust the dose or suspend treatment to reduce the risk of toxicity.

Cobimetinib may cause a variety of adverse reactions, some of which may be serious. Common side effects include gastrointestinal reactions, such as nausea, vomiting, diarrhea, and stomach upset, and skin reactions, such as rash, dryness, photosensitivity, and acne-like skin changes. In addition, patients may experience symptoms such as fatigue, muscle pain, joint swelling, and fever. More serious side effects include cardiac problems (e.g., cardiomyopathy, arrhythmias), increased risk of bleeding, abnormal liver function, visual impairment (e.g., serous retinopathy), and new primary malignancies. Patients should seek medical attention immediately if they experience blurred vision, chest pain, difficulty breathing, unusual bleeding, or severe skin reactions.

There are certain health conditions that patients need to pay special attention to while using cobimetinib. For example, patients with a history of heart disease, retinal disease, liver and kidney dysfunction, bleeding disorders, or muscle diseases should use it with caution under the guidance of a physician. During treatment, cardiac function, liver function, blood routine and ophthalmological conditions should be monitored regularly to detect and deal with possible complications in a timely manner. In addition, because cobimetinib may increase the risk of bleeding, patients should avoid medications that may affect blood clotting and inform their doctor that they are taking this medication before surgery or dental treatment.

The interactions between cobimetinib and other drugs also require attention. Certain drugs (such as strong CYP3A4 inhibitors or inducers) may affect the plasma concentration of cobimetinib, thereby increasing or decreasing its efficacy and toxicity. Therefore, patients should avoid self-use of other medications, including over-the-counter medications and herbal supplements, while taking cobimetinib, and consult a doctor or pharmacist when necessary.

Overall, cobimetinib is an effective targeted therapy, but it needs to be used under strict medical supervision. Patients should follow the doctor's instructions, undergo relevant examinations regularly, and report any abnormal symptoms in a timely manner to ensure the safety and effectiveness of treatment. Through reasonable medication management and adverse reaction monitoring, cobimetinib can provide significant clinical benefits to eligible patients.

Reference link:https://www.gene.com/patients/medicines/cotellic